Tratamento medicamentoso e intervenções nutricionais na distrofia muscular de Duchenne
Austrália e Itália – neste artigo os pesquisadores que estão envolvidas no estudo de drogas para tratamento da distrofia muscular de Duchenne fazem uma revisão das possibilidades de tratamento medicamentoso da doença com ênfase para as intervenções nutricionais e a possibilidade do uso de anti-inflamatórios. O resumo em inglês do artigo pode ser lido abaixo:
(IN PRESS:International Journal of Biochemistry & Cell Biology, 2006) Duchenne Muscular Dystrophy: Focus on pharmaceutical and nutritional interventions
Radley H.G., De Luca A., Lynch G.S., Grounds M.D. – Australia and Italy
Duchenne muscular dystrophy is a lethal X-linked muscle disease resulting from a defect in the muscle membrane protein dystrophin. The absence of dystrophin leads to muscle membrane fragility, muscle death (necrosis) and eventual replacement of skeletal muscle by fat and fibrous connective tissue. Extensive muscle wasting and respiratory failure results in premature death often by the early 20s. This short review evaluates drug and nutritional interventions designed to reduce the severity of muscular dystrophy, while awaiting the outcome of research into therapies to correct the fundamental gene defect. Dietary supplementation with amino-acids such as creatine in combination with specific anti-inflammatory drugs might have immediate realistic clinical benefits although rigorous research is required to determine optimal combinations of such interventions.
